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ABSTRAK 
Tajuk: 
Perkadaran kerintangan Hepatitis B virus terhadap lamivudine dan penentuan faktor-
faktor terjadinya kerintangan tersebut di kalangan pesakit hepatitis B kronik yang 
mengamalkan pengambilan lamivudine dalam jangka masa panjang sebagai rawatan 
tunggal. 
 
Latar Belakang: 
Lamivudine merupakan sejenis anti-virus yang berkesan dalam merawat hepatitis B 
kronik. Walau bagaimanapun, terdapat risiko di mana virus hepatitis B bermutasi dan 
ini menyebabkan kewujudan rintangan terhadap lamivudine. Kerintangan virus 
hepatitis B terhadap lamivudine menyebabkan ianya tidak lagi berkesan dan sekaligus 
kadar pembiakan virus akan meningkat semula dan disusuli pula dengan peningkatan 
ujian-ujian fungsi hati yang berkaitan. Walaupun terdapat alternatif anti-virus lain yang 
lebih berkesan sebagai rawatan pendahuluan seperti entecavir dan tenofovir, terdapat 
masalah tertentu seperti harganya yang mahal yang menyebabkan anti-virus ini tidak 
terdapat di semua pusat rawatan.  
 
Objektif 
Tujuan kajian ini adalah untuk menentukan kadar terjadinya kerintangan virus hepatitis 
B terhadap lamivudine di kalangan pesakit di HUSM, yang mana pengambilannya 
dimulakan di antara tahun 2010 sehingga 2016. Selain itu, kajian ini ingin menentukan 
sekiranya terdapat faktor sehingga wujud kerintangan terhadap lamivudine. Dan yang 
terakhir, kajian ini bertujuan untuk menentukan kadar keberkasanan rawatan 
lamivudine di kalangan pesakit hepatitis B di HUSM. 
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Metodologi 
Ini merupakan kajian retrospektif ke atas 41 pengidap hepatitis B kronik yang diberi 
rawatan lamivudine dari tempoh 2010-2016. Rekod perubatan telah diteliti dan 
maklumat-maklumat yang relevan telah dicatat ke dalam perisian komputer statistik. 
Subjek yang telah mendapat kerintangan virus terhadap lamivudine dan faktor yang 
berkaitan kemudiannya dianalisa. 
 
Keputusan 
Daripada kesemua 41 pesakit yang telah diteliti rekod perubatannya, sebanyak 9 pesakit  
mendapat kerintangan terhadap lamivudine. Ini manjadikan prevalansi semasa tempoh 
6 tahun tersebut adalah 21.9%. Peratusan kes kerintangan lamivudine pada tahun 
pertama, kedua dan ketiga adalah masing-masing sebanyak 4.9%, 12.2% and 21.9%. 
Faktor seperti umur, jantina, kaum, kuantiti HBV DNA sebelum rawatan, ALT dan 
tempoh panjang rawatan adalah tidak signifikan dalam menentukan terjadinya 
kerintangan terhadap lamivudine. Kajian ini juga menunjukkan kadar keberkasanan 
lamivudine dalam merawat Hepatitis B sebanyak 85.9%. 
 
Kesimpulan 
Kadar kekerapan berlakunya kerintangan lamivudine di kalangan pengidap hepatitis B 
kronik yang mengamalkan pengambilan lamivudine sebagai rawatan tunggal dalam 
jangka masa panjang di dalam kajian ini adalah lebih rendah berbanding dengan yang 
dilaporkan di dalam kajian-kajian lain sebelum ini. Walau bagaimanapun, untuk 
membuat sebarang cadangan dalam pemilihan anti-virus, kajian lanjut dengan lebih 
banyak subjek adalah perlu. 
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ABSTRACT 
Title: 
Period Prevalence of Lamivudine Resistance and Its Associated Risk Factor in Chronic 
Hepatitis B Patient Receiving Long Term Lamivudine Monotherapy in Hospital 
Universiti Sains Malaysia (HUSM)  
 
Background: 
Lamivudine is an established treatment options for chronic hepatitis B (CHB), however 
development of viral resistance followed by virological breakthrough made it a less 
favourable as a first line treatment option. While the alternatives such as entecavir and 
tenofovir are favoured for first line options due to its higher genetic barrier to 
resistance, constraints such as financial issue may not make these drugs readily 
available in some practice.  
 
Objectives: 
The aim of the study is to established period prevalence of lamivudine resistance 
among patient with CHB who received Lamivudine from January 2010 to Dec 2016, 
and to explore if there are any factors that associate with development of resistance. 
The study also aims to look at the response rate for those treated with lamivudine 
during the same period. 
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Methods 
This is a retrospective record review done by reviewing record of 41 patients who was 
or on lamivudine during the period of 2010 to 2016. Subjects are CHB patient who are 
treated with lamivudine as a first line monotherapy. All relevant data are gathered from 
the review of case note and recorded in statistical software for analysis. 
 
Results 
Total number of patients included in this study is 41. During the 6 years periods, 9 
patients with lamivudine resistance were detected and this yields an overall period 
prevalence of 21.9%. The cumulative incidence of developing resistance during first 
year, second year and third year while on lamivudine is 4.9%, 12.2% and 21.9% 
respectively. Factors such as age, gender, race, pre-treatment viral load, serum ALT, 
and duration of treatment are shown not associated with development of resistance. In 
terms of response to treatment, this study shows an overall response rate of 89.5%. 
 
Conclusion 
The prevalence and incidence of lamivudine resistance in this study is lower in 
comparison with the prevalence and cumulative incidence cited in many literatures. 
However, further study is warranted to include more patients from other centres in 
order to improve power of this study, before any recommendation can be proposed. 
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CHAPTER 1: INTRODUCTION 
 
1.3 Epidemiology of Adult Hepatitis B Virus Infection 
Hepatitis B virus (HBV) is a double-stranded DNA virus belonging to the 
family of hepadnaviruses. It is estimated that some 240 million people worldwide have 
chronic HBV infection with Africa and Asia being among the regions with the highest 
prevalence (Sarin et al., 2016). The global prevalence of Hepatitis B infection varies 
greatly and can be categorized into high, intermediate and low prevalence country base 
on HBsAg positivity of >8%, 2-7% and <2% respectively (McMahon, 2005).  
 
About one million Malaysians have chronic HBV infection and Hepatitis B 
contributes to 75% of all viral hepatitis cases in Malaysia with male to female ratio of 
2:1. Malaysia is a country under intermediate prevalent country (Raihan, 2016). The 
seroprevalance for HBV surface antigen in Malaysia is estimated around 5%. Figure 1 
shows prevalence of HBV infection trend in Malaysia. From 1990 to 1997, it shows 
that there is steadily decrease trend until sharp rises recorded in 1998. This rises is due 
to the detection from mandatory hepatitis screening for all foreign worker. The decrease 
trend followed after 2000 before it increase again in 2010 due to the rule implemented 
by the government that all cases of hepatitis B to be reported to hospitals (Raihan, 
2016). The rate of HBsAg detection in school children was reduced from 2.5% (for 
those who born in 1985) to 0.4% (for those who born in 1996) due to introduction of 
childhood Hepatitis B vaccination (Raihan, 2016) .Vertical transmission is responsible 
for most of the HBV carrier due to the high viral load in Malaysian child-bearing 
woman (Raihan, 2016).  
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Figure 1: The trend of Hepatitis B prevalence in Malaysia from 1990-2014  
(Adapted from Raihan 2016)  
 
1.4 Hepatitis B Virus Infection in Human 
 
1.2.1 Structure of the Hepatitis B Virus 
 HBV is small, the size of the circulating virion measured at 42-nm Dane particle 
which is comprises of 2 parts - the nucleocapsid and its circulating enveloped. The 
nucleocapsid contains about 3.2 kilobase genome, as a partially double stranded DNA. 
This compact genome encoded for 7 types of viral protein – 3 envelop proteins, the 
nucleocapsid core protein, the secretory Hepatitis B e antigen, the viral reverse 
transcriptase/polymerase and the X protein (Ghany and Liang, 2007). The organization 
of the HBV genome is illustrated in the Figure 2. 
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Referring to Figure 2 above, the inner circle depicts the HBV genome encoded 
for polymerase (dark circle). It attached to the 5’ end of the minus strand and a capped 
oligoribonucleotide (corkscrew) attached to the 5’ end of the incomplete plus strand. 
Two, 11-base pair direct repeats located at the 5’ end of the minus and plus strands - 
DR 1 and DR 2, are important for strand-specific synthesis. The 4 open reading frames 
are shown between the inner and outer circles. These consist of the pre-C/core genes, 
the polymerase gene, the pre-S1, pre-S2 and S genes, and the X gene. Lastly, the outer 
circle shows the 4 major viral mRNAs -the 3.5-kilobase (kb) core or pregenomic 
mRNA, the 2.4-kb pre-S1 mRNA, 2.1-kb pre-S2/S mRNA, and the 0.7 kb X mRNA. 
All mRNAs share a common poly-A 3’ end (Ghany and Liang, 2007). 
Figure 2: Organization of HBV Genome  
(Adapted from Marc Ghany April 2007 DOI:10.1053/j.gastro.2007.02.039) 
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 1.2.2 Replication Cycle of the HBV  
In human host, the HBV replication cycle predominantly takes place in the 
hepatocytes. There is still a debate whether this replication also occurs outside 
hepatocytes. The mechanism in which the HBV attach and enter the hepatocyte is still 
not completely understood. After gained entry into hepatocytes and in the cytoplasm, 
the outer envelope disintegrates. This will release the viral genomes which then make 
its way toward and into host’s nucleus. In the nucleus, a fully double stranded closely 
covalent circular DNA (cccDNA) is produce after the initial circular genome underwent 
a repair process, which mediated by host and viral polymerase enzymes. The cccDNA 
now is ready and now becomes a main template for the production of all the viral 
messenger RNA (mRNA) which are then transport out of nucleus into cytoplasm again 
at which the translation of viral proteins, nucleocapsid assembly and viral replication 
occurs. This viral mRNA strands can be divided into pregenomic mRNA and 
subgenomic mRNA. Pregenomic mRNA is encoded for reverse transcriptase, the core 
and polymerase enzymes. Subgenomic mRNA is necessary for the translation of the 
envelope protein and the X protein. 
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Figure 3: Replication cycle of HBV and molecular target of HBV replication  
(Adapted from Marc Ghany April 2007 DOI:10.1053/j.gastro.2007.02.039) 
 
           
 
Figure 3 illustrates the complex interaction that ultimately leads to 
encapsidation of the pregenomic RNA which takes place in cytoplasm. This complex 
interaction is consists of interplay in between the epsilon, core viral particles, HBV 
polymerase, and various chaperones protein. The generation of negative and then 
positive DNA strands occurs within the viral nucleocapsid and reverse transcriptase is 
essential in this process. Viral assembly takes place in the endoplasmic reticulum (ER). 
‘Mature’ nucleoside is then finally coats with envelope protein before budding and 
release of virion into the blood stream (Ghany and Liang, 2007). 
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 1.2.3 Natural history of HBV infection in Human 
In understanding the natural history of chronic HBV infection, it is important to 
acknowledge that the disease phases that follows reflects a complex interactions 
between the level of HBV replication activity and the host immune reactivity against 
the replicating HBV. The four phases are immune-tolerance phase, immune-clearance 
phase, low replicative phase and reactivation phase. Transition from one phase of 
chronicity to the next is not recognizable in all patients, either because it may not be 
obligatory step in the overall natural course of the infection, or because it is of very 
short duration to allow it to be clinically manifested. The transition from one phase to 
the next along its natural history course is largely depends on the age at which the virus 
is acquired. For example, patient who acquire HBV infection either at birth or within 
first 1-2 years of life, they typically will have a prolonged immune tolerance phase 
followed by equally prolonged immune clearance phase (Sarin et al., 2016).  
 
In the other hand, patient who acquire the virus after early childhood generally 
do not have the immune tolerant phase, but likely to go straight into immune clearance 
phase (characterized by HBeAg seroconversion to anti-HBe and HBV DNA viral load 
is relatively low level or undetectable) and followed by relatively quiet disease after 
that.   In individual with active replication and high viral load burden, damaged 
hepatocytes may progress into cirrhosis and liver failure, and eventually development 
of hepatocellular carcinoma. While majority of chronically infected HBV patient will 
not develop adverse liver outcome, still 15-40% of them will suffered from its 
complication during lifetime (Sarin et al., 2016). 
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1.3 Effect of Vaccination in the Asia Pacific Region 
 
Introduction of Hepatitis B vaccination in newborn has changed the 
epidemiological landscape of Hepatitis B infection. World Health Organisation (WHO) 
has published a report in 2012 demonstrating a robust data that the prevalence of 
chronic Hepatitis B is decreasing in trend from 1990 to 2005 in the most region of the 
world (Ott et al., 2012). In mainland China, the prevalence of HBsAg positivity among 
general population decrease from 9.75% in 1995 to 7.18% in 2006. But the dramatic 
changes is seen in the subset of children less 5 year old, from 9.67% in 1992 to 0.96% 
in 2006 (Liang et al., 2009). Data from Korean studies shows similar encouraging 
decreasing trend of HBsAg prevalence among their teenagers (age 10 to 19 year old), 
from 2.2% in 1998 to 0.12% in 2010 (Kim et al., 2013). 
 
1.4     Lamivudine as Monotherapy in HBV infection 
 
The goal of Hepatitis B treatment is to suppress viral replication before there is 
irreversible damage to the liver. There are few antiviral agents that are effective in 
achieving this suppression. One of them is lamivudine (molecular formula 
C8H11N3O3S), a type of nucleoside analogue reverse transcriptase inhibitor. Lamivudine 
is an enantiomer of 2’, 3’-dideoxy 3’-thiacytidine (ß-L-(-)-2’, 3’-dideoxy 3’-
thiacytidine) which originally developed for the treatment of Human Immunodeficiency 
Virus (HIV) infection. Subsequently it is also discovered that lamivudine also effective 
against HBV infection, irrespective of the HBeAg status as clinical trial has proved its 
effectiveness in both populations (Lai et al., 1998; Tassopoulos et al., 1999). 
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The mechanism behind lamivudine’s ability to inhibit viral replication is via its 
ability to inhibit the DNA polymerase action and DNA replication by targeting the 
HBV-encoded reverse transcriptase. This leads to interference with DNA synthesis 
which will eventually cause DNA chain termination. Before the era of nucleoside 
analogue, treatment of chronic HBV infection is limited to cytokine therapy such as 
alpha interferon. Treatment of HBV infection with nucleoside analogue is much 
preferable compared to interferon due to its convenience (oral form) and favourable 
side effects profile. Nucleoside analogue also reduce the HBV DNA viral load faster 
than the interferon. Treatment of Hepatitis B with lamivudine 100mg daily for 52 
weeks is associated with marked suppression of HBV DNA levels with a median 
reduction of 95%-99% throughout the treatment period in two large phase III trials 
(Dienstag  et al., 1995; Dienstag et al., 1999). One of the earliest efficacy data of 
lamivudine against chronic Hepatitis B infection in Asian population is published in 
1998 by Lai et al. In this randomized control trial, use of lamivudine 100mg daily for 1 
year is associated with higher rate of HBeAg seroconversion, undetectable HBV Viral 
DNA, sustained normalization of ALT compared to placebo group (Lai et al., 1998). In 
2003, Lok et al demonstrated that the efficacy of lamivudine is maintained for 
treatment of HBeAg positive Hepatitis B infection for up to 6 years and it has an 
excellent safety profile (Lok et al., 2003).  Other study demonstrated that HBV 
suppression is maintained in patient on lamivudine for at least 10 years (Sun et al., 
2011).  In a nutshell, lamivudine is efficacious in treatment of HBV infection as 
measured by biochemical (ALT), serological, virological and histological outcome. 
 
 
 
  
9 
 
1.5     HBV Resistance to Lamivudine 
 
While nucleoside analogues is effective and have great safety profile in the 
treatment of chronic HBV infection, it must be used in prolonged duration in order to 
sustain viral suppression. This is due to high rate of virological relapse if the treatment 
ceased. A few studies has shown that once the nucleoside analogue was discontinued, 
HBV DNA levels will return to baseline in most patients with the exception of those 
who achieve a sustained HBeAg seroconversion (Dienstag  et al., 1995; Dienstag et al., 
1999; Lai et al., 1998). The virological relapsed is caused by development of antiviral 
drug resistance, which associated with long-term therapy. Serious consequences may 
occur in those with resistance as rebound virological replication may potentially leads 
to hepatitis flares and death.  
 
  
 
 
 
 
 
Figure 4: The cumulative incidence of lamivudine resistance in comparison 
with other anti-viral (Adapted from Sarin 2016) 
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Lamivudine is potent, but also has the lowest genetic barrier amongst all the 
nucleoside analogues for HBV. Few publications which studied the HBV resistance 
rates towards lamivudine have reported varied figures for prevalence and cumulative 
incidence. Figure 4 illustrates the cumulative incidence of lamivudine resistance and 
other antiviral for HBV. It shows that lamivudine has highest incidence of resistance 
and entecavir is the only nucleoside analogue without any associated clinical resistance.  
 
1.5.1 Definitions of Lamivudine Resistance 
   Lamivudine resistance can be defined in several ways. Genotypic resistance is 
defined as detection of mutation(s) in the HBV genome that are known to confer 
resistance and developed during lamivudine therapy (Sarin et al., 2016). 
Phenotypically, it is defined as decreased susceptibility (in vitro testing) to inhibition by 
lamivudine (Sarin et al., 2016). Lamivudine resistance in HBV infection is clinically 
suspected whenever there is a virological breakthrough, which is defined as increase of 
serum HBV DNA > 1 log IU/ml from nadir of initial response during therapy (Sarin et 
al., 2016). In clinical practice, due to cost associated with measurement of HBV DNA 
viral load, measurement of liver enzyme (particularly serum aminotransferase, ALT) is 
more readily available and measured more frequently along the course of lamivudine 
therapy.  Acute flare of hepatitis in HBV patient is defined as elevations of ALT more 
than twice the baseline value or more than five times the upper limit value (Kumar et 
al., 2006). This hepatitis flare when associated with development of lamivudine 
resistance is termed biochemical breakthrough (Jang et al., 2005). Virological 
breakthrough theoretically must preceded the biochemical breakthrough, but in practice 
this is not always possible to recognized as ALT is more readily and more frequently 
measured compared to HBV DNA viral load.  
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1.5.2 Mechanism of Lamivudine resistance in HBV  
The mechanism that underlies lamivudine resistance is related to how 
lamivudine works in suppressing viral replication. Lamivudine targets the HBV 
polymerase by interfering with its function and due to this interference, it leads to 
newly synthesized DNA chain termination. The HBV polymerase is a multifunctional 
viral protein and it has a pivotal role during viral replication process. It comprises of 
four domains, namely a priming domain, a spacer domain, a catalytic domain and a 
terminal carboxy region that has ribonuclease H activity. The catalytic domain serve as 
RNA-dependent RNA polymerase/DNA polymerase (Ghany and Liang, 2007). The 
sequence structure of the HBV polymerase is illustrated in figure 4. 
 
      Figure 5: HBV polymerase domains  
                  (Adapted from Ghany April 2007 DOI:10.1053/j.gastro.2007.02.039) 
 
As demonstrated in figure 5, the catalytic domain can be further divided into 7 
subdomains. Subdomain C contains a sequence of 4 amino acids: tyrosine, methionine, 
aspartate, aspartate (YMDD). This small subdomain is actually highly conserved 
among viral polymerase/reverse transcriptase. It binds 2 magnesium ions and represents 
the active site of the enzymes. 
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HBV has high replication rate with estimation of 10
12
 virions being produced 
per day. The mutation rate is approximately 10
-5
 substitution/base/cycle. In individual 
with an active replication, this mutation rate translates into approximately 10
10-11
 point 
mutation produced per day. This means that in a relatively small genome virion like 
HBV (~3.2 kilobase pair), all possible single base changes can be produce in just a day. 
 
There are few principal mutations which contribute to the lamivudine resistance. 
Substitution of methionine to valine or isoleucine (rtM204V/I) in the YMDD motif of 
the catalytic domain of HBV polymerase is the commonest one. The rtM204V/I is 
usually associated with the compensatory rtL180M mutation especially in HBV 
genotype A, B and C (Damerow et al., 2010). This mutation leads to changes in the 
DNA polymerase conformational structure which eventually leads to: (1) Steric 
hindrance to decrease binding of lamivudine to the viral polymerase and (2) reduced 
catalytic activity to incorporate lamivudine triphosphate into replicating viral DNA.  
 
The rtM204V/I mutation is not unique to lamivudine. It is also a mechanism 
behind resistance to other L-nucleoside analogue such as telbivudine, but agent like 
entecavir and tenofovir will remain sensitive in those mutant viruses. In vitro study by 
Allen MI demonstrated that the rtM204V/I mutations confer up to 10000 fold resistance 
suggesting that the antiviral response is not restored with lamivudine dose 
increment(Allen et al., 1998). Other mutations that confer lamivudine resistance in 
HBV are rtL80V/I, rtV173L, rtL180M, rtA181V/T, rtT184S, rtQ215S (Ghany and Doo, 
2009; Stuyver et al., 2001). Recent studies suggest that the pattern of mutation is 
related to the HBV genotype. HBV-A favours rtM204V, while HBV B – D prefers 
rtM204I (Mirandola et al., 2012).  
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 1.5.3 Contributing Factors to Development of Anti-Viral Resistance 
 Development of resistant towards antiviral can be due to many factors. 2 of the 
most important one are viral fitness and the potential genetic barrier resistance of the 
anti-viral. Viral fitness is defined as the ability of virus to replicate in defined 
environment and this ability is depends on the replication activity and replication space. 
Replication activity refers to the ability of mutant virus to replicate in the absence of a 
drug compared to the wild-type, drug-sensitive virus. In the other hand, replication 
space refers to the ability of the environment to support replication (hepatocyte in the 
case of HBV). In the case of HBV mutant virus, although the replication fitness was 
initially less, but in the environment where there is a presence of an antiviral agent, 
their population has an advantage and will thrive. Over time, compensatory mutations 
occur. Compensatory mutation refers to secondary mutations that occurs which will 
restores functional defects in the viral polymerase caused by primary mutations. It 
empowers the mutant virus to replicate at near wild type level, leading to development 
of antiviral resistance. 
 
 Genetic barrier to resistance can be regarded as the number of mutations that the 
virus must accumulate before it can replicate effectively in the presence of antiviral. A 
drug with high genetic barrier will have a lower likelihood of resistance because it 
requires a high accumulation of mutations before it becomes ineffective. This antiviral 
property is depends on the structure of the anti-viral compound. 
 
 Host factor also plays significant role in the development of resistant to anti-
viral. Viral replication rate may be different in immunosuppressed individual, thus this 
potentially can affects the rate of mutations development. Ability to achieve effective 
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drug concentrations quickly is also crucial as the potency of a drug is reflected by how 
rapidly it can suppress viral replication; the more rapid, the lower the risk of developing 
antiviral resistance. This is not always easy to achieve especially in obese patient, or 
those who are not compliant to therapy. 
 
1.5.4 Clinical Significance of Lamivudine Resistance in HBV 
The incidence of lamivudine resistant has been evaluated in several studies. 
Table 1 below summarizes the cumulative incidence quoted by European Association 
for the Study of the Liver (EASL) and Asian Pacific Association for the Study of the 
Liver (APSL) in their HBV infection Clinical Practice Guidelines. It highlights that the 
percentage is higher with prolonged duration of the therapy ("EASL 2017 Clinical 
Practice Guidelines on the management of hepatitis B virus infection," 2017). 
  
Duration on 
Lamivudine 
Cumulative Incidence 
EASL 2017 APASL 2016 
1 year 24% 23% 
2 year 38% 46% 
3 year 49% 55% 
4 year 67% 71% 
5 year 70% 80% 
 
Table 1: Cumulative incidence of Lamivudine Resistance 
 
 Study by Liaw et al demonstrated that resistance to lamivudine among the HBeAg 
positive chronic hepatitis B patient on lamivudine is 24% (81 of 335) during the clinical 
trial (Liaw et al., 2000). In HBeAg negative population, Osman et al demonstrated that 
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overall virological breakthrough rate of 35% (Osman, 2011). Lok et al shows that the 
rate of lamivudine resistance is increase with longer duration of therapy, showing 
percentage of patient with rtM204V/I mutation of 19%, 23%, 62%, 76% and 80% at 
<1year, 1-2 year, 2-3 year, 3-4 year and 4-5 year respectively (Lok et al., 2003). 
 
Diagnosing HBV resistance against lamivudine can be done genotypically by 
detecting YMDD variants by means of polymerase chain reaction (PCR). The test will 
recognize if the mutation is present or not and also a specific mutation subtype. 
However this is rarely done in clinical practice. Virological breakthrough, and 
biochemical breakthrough is clinically more feasible way to detect presence of 
resistance. 
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1.6    Rationale of Study   
Data on HBV resistance to lamivudine have a significant impact on the many HBV 
infection treatment guidelines. Recently updated Asia Pacific Association Study of the 
Liver (APASL) Clinical Practice Guidelines on the management of hepatitis B in 2016 
have proposed tenofovir and entecavir as a first line agent in treatment naïve individual 
(Sarin et al., 2016). This highlights that the role of lamivudine as first line monotherapy 
is fading. Similarly, lamivudine is no longer first line antiviral for both American 
Association for the Study of Liver Disease (AASLD) and European Association for the 
Study of the Liver (EASL) ("EASL 2017 Clinical Practice Guidelines on the 
management of hepatitis B virus infection," 2017; Terrault et al., 2016). 
While entecavir or tenofovir is the preferred first line agent due to its superior 
clinical efficacy and safety profile compared to lamivudine, the associated extra cost 
that comes with it may not make it readily available for all patients. This is 
exceptionally true in current challenging economic climate where a tight financial 
resource is common including healthcare budget cut.  APASL acknowledge in their 
CPG in 2016 that lower cost for lamivudine therapy is one of the reason why it is still a 
commonly used therapy in many of Asian country. Lamivudine is an inexpensive drug 
and is still clinically relevant especially in a population where the rate of resistance is 
known to be low. 
In this study, we aimed to establish lamivudine resistance rate in our cohort of HBV 
patient. Based on our clinical experience, we observe that our resistance rate is lower 
compared with what was being reported in the literature. If the lower resistance rate is 
observed in our centre, this is a big supporting point to the use of lamivudine as a first 
line therapy for treatment of chronic HBV infection. 
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 The proportion of lamivudine resistant case in this study possibly can be 
reported in term of prevalence and period prevalence. Period prevalence takes account a 
defined period of time in its denominator, as compared to prevalence where is just at 
certain point of time. This study involves a specified period of time of 6 years from 
2010-2016, so period prevalence was deemed more appropriate measure in this study. 
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CHAPTER 2: RESEARCH OBJECTIVE 
 
2.1 General Objective 
The aim of the study was to established period prevalence of lamivudine 
resistance among patient with CHB who received lamivudine from January 
2010 to December 2016, and to explore if there were any factors associated with 
development of resistance. The study also aimed to look at the response for 
those with CHB during the same period. 
 
2.2 Specific Objective: 
 To determine the period prevalence and cumulative incidence of lamivudine 
resistance in chronic hepatitis B patient receiving long term lamivudine in 
HUSM from 2010-2016. 
 To determine the associated factor for development of lamivudine resistance  
 To determine the period prevalence of patient with biochemical, serological or 
virological response among chronic hepatitis B patients receiving long term 
lamivudine in HUSM from 2010-2016 
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CHAPTER 3: METHODOLOGY 
3.1 Research Design 
This is retrospective record review involving patient with CHB 
receiving lamivudine in HUSM Gastroenterology Clinic from 2010-
2016 
3.2 Study Location 
Gastroenterology Clinic HUSM and Record Office HUSM 
3.3 Study Duration 
 January 2017 – Nov 2017 
3.4 Study Approval 
This study was approved by the Research and Ethic Committee, 
Universiti Sains Malaysia with JEPeM study protocol code 
USM/JEPeM/17080363 
 3.5 Reference Population 
Patient who were diagnosed with HBV infection, antiviral naive 
and received lamivudine as first line monotherapy in HUSM from year 
January 2010 to December 2016. 
3.6 Sampling Method 
List of all patients who was prescribed lamivudine from 2010-
2016 were extracted by using electronic pharmacy record. Their medical 
records were then traced from record office and examined for inclusion 
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and exclusion criteria and those who were eligible, all the necessary 
information is extracted based on proforma (Appendix A) 
 3.7 Inclusion Criteria 
 Adult male or female (>18 years old)  
 Positive Serology for Hepatitis B Surface antigen (HBsAg) at 
diagnosis 
 Detectable Serum HBV DNA by quantitative PCR assay prior to 
lamivudine initiation 
 Never received prior antiviral therapy for HBV infection before 
3.8      Exclusion Criteria 
 Co-infection with Hepatitis C Virus or HIV 
 Patient receiving steroids or immunosuppression (such as 
chemotherapy) 
 Patient with organ transplant 
 Known to be pregnant or breastfeeding 
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3.9 Definitions of outcome measurement used in this study 
3.9.1   Lamivudine Resistance to HBV  
In this study, we defined lamivudine resistance as patient who is currently or 
previously on lamivudine given as first line monotherapy for HBV infection and 
developed any of these 3 following criteria while on lamivudine therapy:- 
(A) Virological breakthrough - Increase of HBV DNA > 1 log IU/ml from nadir 
(B) Biochemical breakthrough – increase of ALT by 2 times of nadir  
(C) Increase of HBV DNA and/or ALT level that are not up to the level to meet 
Criteria (A) or (B), nonetheless there is documentation stated that the 
treating gastroenterologist decided to discontinue lamivudine and change to 
other anti-viral against HBV in the absence of other factor such as 
intolerable drug side effects. 
 This definition is rather very liberal definition for lamivudine resistance. Previous 
studies that look at the resistant rate used virological breakthrough or genotypic 
detection, which in our setting are not routinely done. Biochemical breakthrough as a 
surrogate marker lamivudine resistance has been evaluated in one study by Jang et al 
(Jang et al., 2005). The liberal use definitions of resistance in this study will have more 
impact on the clinical practice if we are able to demonstrate lower resistance rate 
compared to historical rate. 
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 Resistance to lamivudine was reported in terms of its period prevalence and 
cumulative incidence. In this study, period prevalence of lamivudine resistance is the 
number of patient who developed resistance to lamivudine divided by total number of 
patient who is on lamivudine over a 6 years period of 2010 to 2016.  
 
Cumulative incidence of lamivudine resistance is calculated by following formula 
 
 Cumulative Incidence = 
 
 
3.9.2 Treatment Response  
Treatment response after lamivudine initiation was assessed via several parameters. 
Subjects were regarded as having response to lamivudine if meet any one of these 3 
criterias: 
1. Virological Response – HBV DNA load of <2000IU/ml after 6 months of 
starting lamivudine 
2. Biochemical response – normalization of ALT level 
3. Serological response – HBeAg loss in a previously HBeAg positive patient  
 
3.9.3 Variable Definition 
Duration of treatment 
Calculated in months from date of lamivudine initiated to the date it was 
discontinued. It may be discontinued due to following reasons: Development of 
resistance or because of total treatment duration have deemed completed by treating 
gastroentroentrologist. 
Number of new case of lamivudine resistance  
    Number of subjects on lamivudine at risk 
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Pre-treatment HBV DNA load 
Measured HBV DNA viral load in IU/ml before the initiation of lamivudine therapy 
 
Pre-treatment ALT level 
The last measured serum alanine transaminase before the intiation of 
lamivudine therapy. In addition to the absolute value (in IU/L), ALT level also was 
categorized into 3 groups – normal, minimally raised and raised. Normal ALT is 
defined as ALT level within labarotory reference range. Minimally raised serum 
ALT level is defined as increment of ALT level up to two times upper limit normal, 
and raised serum ALT is define as increment of more than two times upper limit 
normal.  
 
Baseline HBeAg status 
Presence of HBe antigen before the initiation of lamivudine therapy 
 
Cirrhotic status 
Presence or absence of liver cirrhosis based on the result of the ultrasound 
abdomen done at any point during the course of follow up 
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3.10 Sample Size Calculation 
Objective 1 
Sample size is based on overall prevalence of lamivudine resistance of 
35% (Osman, 2011) 
N = [z / Δ] 2 p ( 1 – p ) 
       P = prevalence of lamivudine resistance 0.35  
       Z = 1.96 for 95% CI 
       Δ (precision) = 0.1 
       N = [ 1.96 / 0.1] 
2
 0.35 ( 1 – 0.35 )  
           = 87 
Missing data estimated to be 10%  
The sample of 96 will be required at analysis stage.  
 
 
 
 
 
 
 
 
 
 
 
 
